评估 Iovera®° 系统对上肢痉挛受试者的有效性和安全性的研究
一项多中心、随机、双盲、假对照研究,评估 Iovera®° 系统在上肢痉挛受试者中的有效性和安全性
This multicenter, randomized, double-blind, sham-controlled study is designed to evaluate the efficacy and safety of the iovera° system in subjects with upper extremity spasticity. A total of approximately 132 subjects will be enrolled; 88 subjects will receive treatment with the iovera° system and 44 subjects will receive sham treatment (sham iovera° system treatment).
研究概览
详细说明
The screening and treatment may occur on the same day or be separated by as much as 30 days. All screening procedures must be completed, and criteria must be met before a subject is randomly assigned in the study. After random allocation to treatment, the subject will be scheduled for treatment (Day 1).
For all subjects, a Baseline (Day 1, pretreatment) Modified Ashworth Scale (MAS) score, Modified Tardieu Scale, and Goal Attainment Scale (GAS) score will be assessed and recorded before treatment on Day 1 (treatment day).
On Day 1 (treatment day), subjects will be reassessed for eligibility and randomly assigned in a blinded fashion (2:1) to receive either the iovera° system treatment or sham treatment. The study device will be used per the iovera° system User Guide on subjects who are prepared with local anesthetic (lidocaine 1%) only.
Local anesthetic will be injected subcutaneously into the treatment area. Ultrasound guidance will then be used to identify the specific target nerves to be studied. The targets of treatment are the medial and lateral pectoral nerves, and musculocutaneous nerve (motor branches to brachialis, and biceps brachii). A catheter will be used to guide the device needle. All subjects will have all target nerves treated. Nerve stimulation will also be employed as needed to assist in making an accurate determination regarding the location of the target nerves of interest. Up to two unblinded (1 primary and 1 backup) study staff (trained in the iovera° system treatment under ultrasound guidance) will be assigned per site to perform the study treatment procedures unless approved in advance in writing by the Sponsor on a case-by-case basis. The designated unblinded study staff must not participate in any other study-related assessments following treatment.
Each subject will be followed for 13 weeks post-treatment. The follow-up visits will be conducted at Week 3/Day 21 (±3), Week 7/Day 49 (±3), and Week 13/Day 91 (±5). Subjects will be assessed for efficacy and safety outcomes parameters.
研究类型
注册 (实际的)
阶段
- 不适用
联系人和位置
学习地点
-
-
California
-
Downey、California、美国、90242
- Rancho Los Amigos National Rehabilitation Center
-
Santa Monica、California、美国、90403
- Source Healthcare - Santa Monica
-
-
Florida
-
Bradenton、Florida、美国、34209
- Nova Clinical Research, LLC
-
Sarasota、Florida、美国、34239-2921
- Sarasota Memorial Hospital (SMH)
-
-
Georgia
-
Atlanta、Georgia、美国、30309
- Shepherd Center
-
-
Kansas
-
Overland Park、Kansas、美国、66211
- Kansas Institute of Research - Kansas City Bone & Joint Clinic
-
-
Missouri
-
Columbia、Missouri、美国、65212-0001
- University of Missouri Health Care - University Hospital
-
St Louis、Missouri、美国、63110-1032
- Washington University School of Medicine
-
-
New Jersey
-
Camden、New Jersey、美国、08103
- Cooper University Healthcare
-
-
New York
-
New York、New York、美国、10029-6501
- Mount Sinai Health System - Faculty Practice Associates (FPA)
-
-
Pennsylvania
-
Elkins Park、Pennsylvania、美国、19027
- Moss Rehab Physical Medicine Associates
-
Pittsburgh、Pennsylvania、美国、15213
- University of Pittsburgh Medical Center (UPMC) - Presbyterian Hospital
-
-
Texas
-
Dallas、Texas、美国、75390
- University of Texas Southwestern Medical Center
-
Houston、Texas、美国、77030
- University of Texas Health Houston/TIRR
-
-
Virginia
-
Richmond、Virginia、美国、23238
- Virginia iSpine Physicians, PC
-
-
Washington
-
Spokane、Washington、美国、99202
- St. Luke's Rehabilitation Institute/Main Campus
-
-
Wisconsin
-
Greenfield、Wisconsin、美国、53228
- Center for Neurological Disorders - Gamma Therapeutic Center
-
Milwaukee、Wisconsin、美国、53226-3548
- Froedtert and Medical College of Wisconsin - Milwaukee
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Male or female, 18 years and above.
- A confirmed diagnosis of any cerebral or spinal condition, at least 6 months before Screening, resulting in spasticity of the muscles controlling the shoulder and elbow.
- Not on oral medications for spasticity management or if on any oral medications, the oral medication taken chronically for spasticity management (eg, oral baclofen) must be maintained at a stable dose for at least 4 weeks before screening for the study.
- Not on an intrathecal baclofen pump or if on an intrathecal baclofen pump for spasticity management, must be maintained at a stable dose for six months or more before screening for the study.
- Must have a score on the Modified Ashworth Scale of 2 or more in the targeted area (shoulder and elbow) at Screening and at Baseline (Day-1 pretreatment).
- A diagnostic nerve block using lidocaine (1% lidocaine, 2 to 3 mL per target nerve) showing a positive response (at least one point reduction from the screening Modified Ashworth Scale score for elbow extension and shoulder abduction) to the targeted nerves, should be performed within 30 days to at least 6 hours before study treatment. The diagnostic nerve block effect must be completely resolved before pretreatment evaluation and the study treatment.
- Subject, in the investigator's opinion, will not be exposed to unacceptable risk by participation.
- Able to provide informed consent, adhere to the study schedule, and complete all study assessments.
Exclusion Criteria:
- History of stroke, traumatic brain injury, and/or spinal cord injury in less than 6 months.
- Diagnosis of cryoglobulinemia, paroxysmal cold hemoglobinuria, cold urticaria, or Raynaud's disease.
- History of neurotoxin injections within the past 3 months.
- Previous injection with phenol or ethyl alcohol at any time in the target areas (shoulder or elbow).
- Previous surgical intervention that altered the target neuroanatomy of the upper limb.
- Current or planned enrollment in an investigational drug or device study for the management of spasticity for the duration of the study.
- Medical instability that interferes with tolerability to spasticity treatment with the study device as per the investigator's discretion.
- Any hospitalization within 4 weeks before Screening
- Diagnosis of amyotrophic lateral sclerosis or any lower motor neuron conditions
- Allergy or intolerance to amide local anesthetics.
- Any skin condition in or around the target area that, in the opinion of the investigator, could adversely impact treatment.
- Currently pregnant, nursing, or planning to become pregnant during the study.
- History of, suspected, or known addiction to or abuse of illicit drug(s), prescription medicine(s), or alcohol within the past 2 years.
- Uncontrolled anxiety, schizophrenia, or other psychiatric disorder that, in the opinion of the investigator, could interfere with study assessments or compliance.
- Subject, in the opinion of the investigator, is not a suitable candidate for study participation (eg, history of multiple missed office visits, any related upper limb injury).
- Subject is unable to adhere to the assessment schedule.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
有源比较器:iovera°系统治疗
|
subjects will receive ultrasound-guided iovera° system treatment |
|
假比较器:假手术治疗
|
subjects will receive ultrasound-guided iovera° sham system treatment |
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
测量的肘部改良阿什沃斯量表分数相对于基线的变化(0 到 4,其中较低分数代表正常肌张力,较高分数代表痉挛)
大体时间:第 13 周
|
第 13 周
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
肩部改良 Tardieu 量表相对基线的变化(肩部外展)
大体时间:第 13 周
|
第 13 周
|
|
测量的肩部(肩部外展)评分相对于基线的变化
大体时间:第 13 周
|
第 13 周
|
|
肘部改良 Tardieu 量表相对于基线的变化(0 到 5,较低的分数代表没有阻力,较高的分数代表关节不动;相对于基线的角度增加 [R1 和 R2] 代表改善)
大体时间:第 13 周
|
第 13 周
|
|
由盲法、训练有素、有执照的医务人员评估的目标达成量表分数相对于基线的变化(-2 至 +2,其中较低分数代表较少的预期结果,较高的分数代表较高的预期结果)
大体时间:第 13 周
|
第 13 周
|
其他结果措施
结果测量 |
大体时间 |
|---|---|
|
立即(3 小时内)测量肘部改良 Tardieu 量表相对于基线的变化
大体时间:治疗后第 1 天、第 3 周和第 7 周。
|
治疗后第 1 天、第 3 周和第 7 周。
|
|
立即(3 小时内)测量肩部(肩外展)改良 Tardieu 量表相对于基线的变化
大体时间:治疗后第 1 天、第 3 周、第 7 周和第 13 周
|
治疗后第 1 天、第 3 周、第 7 周和第 13 周
|
|
立即(3 小时内)测量肩部改良 Tardieu 量表(前屈、外旋)相对于基线的变化
大体时间:治疗后第 1 天、第 3 周、第 7 周和第 13 周
|
治疗后第 1 天、第 3 周、第 7 周和第 13 周
|
|
立即(3 小时内)测量肘部改良 Ashworth 量表评分相对于基线的变化
大体时间:治疗后第 1 天、第 3 周和第 7 周
|
治疗后第 1 天、第 3 周和第 7 周
|
|
立即(3 小时内)测量肩部(肩外展)改良 Ashworth 量表评分相对于基线的变化
大体时间:治疗后第 1 天、第 3 周和第 7 周
|
治疗后第 1 天、第 3 周和第 7 周
|
|
立即(3 小时内)测量肩部改良 Ashworth 量表评分(前屈、外旋)相对于基线的变化
大体时间:治疗后第 1 天、第 3 周和第 7 周
|
治疗后第 1 天、第 3 周和第 7 周
|
|
治疗后 13 周内改良 Ashworth 量表评分相对于基线的变化,通过肘部曲线下面积 (AUC) 测量(肘部伸展)
大体时间:第 13 周
|
第 13 周
|
|
治疗后 13 周内通过 AUC 测量的肩部改良 Ashworth 量表评分相对于基线的变化(肩部外展、肩部前屈、外旋)
大体时间:第 13 周
|
第 13 周
|
|
由盲法、经过培训、有执照的医务人员评估的目标达成量表评分相对于基线的变化
大体时间:在第 3 周和第 7 周
|
在第 3 周和第 7 周
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.